Larvol Delta - BioAtla-and-GATC-Health-Announce-a-40-Million-Special-Purpose-Vehicle-SPV-Transaction-to-Advance-Ozuriftamab-Vedotin-OzV-into-a-Registrational-Trial-for-2L-Oropharyngeal-Squamous-Cell-Carcinoma-OPSCC

ozuriftamab vedotin (BA3021) - BioAtla

https://www.globenewswire.com/news-release/2025/12/31/3211742/0/en/BioAtla-and-GATC-Health-Announce-a-40-Million-Special-Purpose-Vehicle-SPV-Transaction-to-Advance-Ozuriftamab-Vedotin-Oz-V-into-a-Registrational-Trial-for-2L-Oropharyngeal-Squamous-.html

Dec 31, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next